- CEL-SCI Corporation (CVM, Financial) announces a 1-for-30 stock combination effective May 20, 2025.
- The combination aims to increase the share price to attract more investors and comply with major US stock exchange requirements.
- The CEO anticipates major catalysts in the coming months that could increase investor interest.
CEL-SCI Corporation (CVM) announced during its annual Shareholder's Meeting on May 19, 2025, that a 1-for-30 combination of its common stock has been authorized and will be implemented on May 20, 2025. Shareholders can expect that for every 30 shares of common stock, they will receive one new share. The company's ticker symbol remains CVM, but shares will trade under a new CUSIP number 150837 706 when the market reopens.
The restructuring move aims to address CEL-SCI's low stock price which has been a barrier for some investment funds. By consolidating shares, the company intends to bring the share price to levels that attract more investors and comply with US stock exchange preferences for higher-priced shares. CEI-SCI CEO Geert Kersten expressed optimism about potential upcoming catalysts and emphasized the importance of this move in advancing the company's goals.
The company reiterated that shareholders do not need to exchange their current stock certificates for new ones, though they may choose to do so. Any fractional shares resulting from the combination will be rounded to the nearest whole number, ensuring that no shareholders are eliminated in the process.
CEL-SCI, a biotechnology firm with operations in Vienna, Virginia, and Baltimore, Maryland, focuses on boosting patients' immune responses before surgical and therapeutic interventions. Its lead investigational product, Multikine, has shown promise in clinical trials and has received FDA Orphan Drug designation for head and neck cancer treatments.
